In summary, siRNA nanoparticle targeting Usp20 exhibits a good therapeutic effect on metabolic diseases caused by a HFD or a high-cholesterol diet, with reduced lipid levels, decreased atherosclerosis, and increased thermogenesis and insulin sensitivity, demonstrating that siRNA targeting Usp20 holds great promise for treating metabolic syndrome. Here, INS is linked to atherosclerosis.